Enanta Pharmaceuticals (ENTA) financial statements
Enanta Pharmaceuticals reported revenue of $65M in fiscal 2025, down 3.3% a year over 9 years.
Net income was -$82M and the operating margin -130.7%, against 34.9% in 2016.
Free cash flow was -$32M.
The diluted share count rose 11% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Enanta Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $103M | $207M | $205M | $122M | $97M | $86M | $79M | $68M | $65M |
| Research and development | $40M | $57M | $95M | $142M | $137M | $174M | $165M | $164M | $131M | $107M |
| Selling, general and admin | $17M | $21M | $23M | $26M | $27M | $33M | $45M | $53M | $58M | $44M |
| Operating income | $31M | $25M | $88M | $37M | -$42M | -$110M | -$124M | -$137M | -$122M | -$85M |
| Interest expense | $45,000 | $40,000 | — | — | — | $0 | $0 | $5M | $11M | $8M |
| Pre-tax income | $33M | $27M | $93M | $46M | -$35M | -$108M | -$122M | -$131M | -$118M | -$84M |
| Income tax | $11M | $9M | $21M | -$826,000 | $1M | -$29M | -$433,000 | $3M | -$2M | -$2M |
| Net income | $22M | $18M | $72M | $46M | -$36M | -$79M | -$122M | -$134M | -$116M | -$82M |
| EPS (diluted) | $1.13 | $0.91 | $3.48 | $2.21 | -$1.81 | -$3.92 | -$5.91 | -$6.38 | -$5.48 | -$3.84 |
| Diluted shares | 19M | 19M | 21M | 21M | 20M | 20M | 21M | 21M | 21M | 21M |
| Operating margin | 34.9% | 23.9% | 42.7% | 17.9% | -34.0% | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% |
| Net margin | 24.5% | 17.2% | 34.8% | 22.6% | -29.5% | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |
Balance sheet
Fiscal years, from Enanta Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $210M | $224M | $309M | $335M | $387M | $244M | $249M | $370M | $248M | $189M |
| Receivables | $13M | $11M | $67M | $51M | $23M | $24M | $20M | $9M | $7M | $7M |
| Total current assets | $232M | $238M | $380M | $402M | $437M | $319M | $312M | $423M | $300M | $204M |
| Property, plant and equipment | $8M | $8M | $8M | $11M | $9M | $6M | $6M | $12M | $33M | $35M |
| Total assets | $281M | $327M | $414M | $490M | $486M | $439M | $375M | $462M | $377M | $281M |
| Total current liabilities | $8M | $21M | $16M | $23M | $24M | $36M | $30M | $63M | $58M | $49M |
| Total liabilities | $11M | $25M | $21M | $27M | $31M | $39M | $54M | $246M | $248M | $216M |
| Shareholders' equity | $270M | $302M | $394M | $462M | $456M | $399M | $321M | $217M | $129M | $65M |
| Net debt | -$17M | -$66M | -$64M | -$51M | -$87M | -$57M | -$44M | -$85M | -$37M | -$32M |
Cash flow
Fiscal years, from Enanta Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $36M | $53M | $29M | $71M | $7M | -$70M | -$85M | -$103M | -$79M | -$19M |
| Capital spending | $5M | $3M | $3M | $5M | $1M | $750,000 | $2M | $9M | $18M | $13M |
| Free cash flow | $31M | $50M | $26M | $66M | $6M | -$71M | -$87M | -$112M | -$97M | -$32M |
| Stock-based compensation | $9M | $13M | $16M | $19M | $20M | $21M | $27M | $28M | $27M | $19M |
| Free cash flow margin | 35.2% | 48.8% | 12.7% | 32.2% | 4.6% | -72.9% | -100.9% | -141.7% | -143.0% | -49.2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ENTA.
Open ENTA in InvestinglyQuestions
What was Enanta Pharmaceuticals's revenue in 2025?
$65M in fiscal 2025, from its 10-K filing.
How much free cash flow does Enanta Pharmaceuticals generate?
-$32M in fiscal 2025 (operating cash flow minus capital spending).
From Enanta Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.